Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis(CRTICAS)

NCT01994161 | Unknown DMC

• 1 other identifier: XW125-S003
• Study Type: observational
• Target: 840
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is an prospective, government-funded registration study that will observe the safety and effectiveness of intracranial stenting for preventing stroke during a mean follow-up of 12 months in patients with symptomatic stenosis of a major intracranial artery (MCA, carotid, vertebral, basilar). This trial will be launched by Xuanwu Hospital, Capital University of Medical Science, with 20 collaborators participating. Enrollment will begin in 2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is scheduled to complete in 2015. As we know, SAMMPRIS is flawed with defect in design, heterogeneity in experience and credentials of operators and high rate of complication; Whether the interventional therapy for symtomatic intracranial artery stenosis is effective or not remained resolved. This trial has been modified based on SAMMPRIS in order to acquire the data for China: Technique, experience, and credential of the operators are closely related with perioperative complications in PTAS. The investigators select 50 large-scale medical centers for participation on the basis of geographical distribution. All the participants are ranked as top in China. They have the most experienced surgeons or interventionist in China, and are fully qualified for this trial. This will guarantee the success and safety of technique, maintain the continuity of operator's experience, and make the complication rate as low as possible.

Conditions

Ischemic Stroke

Keywords

ischemic stroke; intracranial stenting; vascular risk factor management

Outcome Measures

Primary Outcomes (1)

• Ischemic stroke, death or cardiovascular events

  The participants who suffer from Ischemic stroke, death or cardiovascular events after enrollment or any revascularization procedure of the qualifying lesion in the territory of the symptomatic intracranial artery

  30 days

Secondary Outcomes (4)

• Any stroke, or death

  beyond 30 days through 6 months

• the number of participants who suffer from restenosis (>50%) related to intracranial stenting

  up to 12 months

• the changes from baseline in mRS, national institutes of health stroke scale (NIHSS) and Barthel Index

  at 7 days, 30 days, 6 months, 12 months, 24 months and 36 months

• the number of participants who survives in all patients

  beyond 12 months to 36 months

Study Arms (1)

Intracranial stenting group

all the participants in this group will be performed with intracranial stenting

Procedure: intracranial stenting

Interventions

intracranial stenting PROCEDURE

all the participants in this group will be performed with intracranial stenting \--------------------------------------------------------------------------------

Intracranial stenting group

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This trial is an prospective, government-funded registration study that will observe the safety and effectiveness of intracranial stenting for preventing stroke during a mean follow-up of 3 years in patients with symptomatic stenosis of a major intracranial artery (MCA, carotid, vertebral, basilar). This trial was launched by Xuanwu Hospital, Capital University of Medical Science, with 20 collaborators participating. Enrollment will begin in 2013, and it aims to have a sample size of 840 subjects in 2 years. The trial is scheduled to complete in 2015.

You may qualify if:

• Symptomatic status: as evidenced by TIA or non-severe stroke within the past 12 months attributed to 70% to 99% stenosis of a major intracranial artery (carotid artery, MCA stem \[M1\], vertebral artery, or basilar artery).
• Degree of stenosis: 70%-99%; (Stenosis must be confirmed by catheter angiography for enrollment in the trial,WASID method)
• Age:30-80 years;
• No fresh infarctions identified on MRI (indicated as high signals on DWI series) upon enrollment
• No massive cerebral infarction (\>1/2 MCA territory), intracranial hemorrhage, epidural or sub-dural hemorrhage, and intracranial brain tumor on CT or MRI scan
• mRS scale score of \<=2
• Target vessel reference diameter must be measure d to be 2.00 mm to 4.50 mm; target area of stenosis is \<=14 mm in length
• Patient is willing and able to return for all follow-up visits required by the protocol
• Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed informed consent.

You may not qualify if:

• Untoward reaction to anesthesia.
• Any condition that precludes proper angiographic assessment or makes percutaneous arterial access unsafe.
• Tandem extracranial or intracranial stenosis that is proximal or distal to the target intracranial lesion
• Previous treatment of target lesion with a stent, angioplasty, or other mechanical device.
• Any aneurysm proximal to or distal to stenotic intracranial artery. Intracranial tumor (except meningioma) or any intracranial vascular malformation
• Computed tomographic or angiographic evidence of severe calcification at target lesion
• Stroke of sufficient size (\>5cm on CT or MRI) to place patient at risk of hemorrhagic conversion during the procedure.Hemorrhagic transformation of an ischemic stroke within the past 15 days.
• Previous spontaneous intracerebral (parenchymal) or other intracranial (subarachnoid, subdural, or epidural) hemorrhage within 30 days
• Untreated chronic subdural hematoma \>5 mm in thickness
• Intracranial arterial stenosis related to arterial dissection, moya-moya disease or any known vasculitic disease;
• MI within previous 30 days
• Any episode of paroxysmal atrial fibrillation within the past 6 months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation
• Intolerance or allergic reaction to any of the study medications, including aspirin, clopidogrel, heparin, nitinol, and local or general anaesthesia History of life-threatening allergy to contrast dye. If not life-threatening and can be effectively pretreated, patient can be enrolled at physicians discretion
• Recent GI bleed that would interfere with antiplatelet therapy. Active bleeding diathesis or coagulopathy; active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \<125,000, hematocrit \<30, Hgb \<10 g/dl, uncorrected INR \>1.5, bleeding time \>1 minute beyond upper limit normal, or heparin-associated thrombocytopenia that increases the risk of bleeding, uncontrolled severe hypertension (systolic BP\>180 mm hg or diastolic BP\>115 mm hg), severe liver impairment (AST or ALT \>3 times normal, cirrhosis), creatinine \>265.2μmol/l (unless on dialysis)
• Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 90 days after enrollment

Sponsors & Collaborators

• Xuanwu Hospital, Beijing: lead

Study Sites (1)

Department of neurosurgery, Xuanwu hospital

Beijing, 100053, China

RECRUITING

Related Publications (7)

• Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.

  PMID: 21899409 RESULT

• Feigin VL. Stroke epidemiology in the developing world. Lancet. 2005 Jun 25-Jul 1;365(9478):2160-1. doi: 10.1016/S0140-6736(05)66755-4. No abstract available.

  PMID: 15978910 RESULT

• Zaidat OO, Klucznik R, Alexander MJ, Chaloupka J, Lutsep H, Barnwell S, Mawad M, Lane B, Lynn MJ, Chimowitz M; NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology. 2008 Apr 22;70(17):1518-24. doi: 10.1212/01.wnl.0000306308.08229.a3. Epub 2008 Jan 30.

  PMID: 18235078 RESULT

• Fiorella D, Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, Hanel RA, Woo H, Rasmussen PA, Hopkins LN, Masaryk TJ, McDougall CG. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke. 2007 Mar;38(3):881-7. doi: 10.1161/01.STR.0000257963.65728.e8. Epub 2007 Feb 8.

  PMID: 17290030 RESULT

• Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi: 10.1056/NEJMoa043033.

  PMID: 15800226 RESULT

• Han Z, Wang T, Li L, Fan J, Wang R, Zheng Y, Yan F, Zhao H, Luo Y, Jiao L. Expression profiles and potential clinical significance of circular RNAs in peripheral neutrophils of patients with intracranial atherosclerotic stenosis. Brain Circ. 2025 Jul 3;11(3):200-211. doi: 10.4103/bc.bc_16_24. eCollection 2025 Jul-Sep.

  PMID: 40842453 DERIVED

• Zhao F, Wang T, Luo J, Gao H, Zheng Y, Wang R, Fan J, Zhao H, Han Z, Luo Y, Jiao L. Endothelial Glycocalyx in Cerebral Infarction After Endovascular Treatment in Patients With Intracranial Artery Stenosis. CNS Neurosci Ther. 2025 Aug;31(8):e70545. doi: 10.1111/cns.70545.

  PMID: 40808328 DERIVED

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Feng Ling, MD

  Xuanwu Hospital, Capital University of Medical Sciences, Beijing, China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Liqun Jiao, MD

CONTACT

86-10-83198899; jiaoliqun@gmail.com

Yabing Wang, MD

CONTACT

86-10-83198990; wangyabing@foxmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 14, 2013
• First Posted: November 25, 2013
• Study Start: December 1, 2012
• Primary Completion: December 1, 2014
• Study Completion: December 1, 2015
• Last Updated: November 25, 2013

Record last verified: 2013-10

Locations

CN (1)